Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):19–23. doi: 10.1038/sj.bjc.6690645

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA

S A Watson 1, T M Morris 1, H M Collins 1, L J Bawden 2, K Hawkins 2, E A Bone 2
PMCID: PMC2374341  PMID: 10487607

Abstract

Inhibition of matrix metalloproteinases (MMPs) is an attractive approach to adjuvant therapy in the treatment of cancer. Marimastat is the first orally administered, synthetic MMP inhibitor to be evaluated, in this capacity, in the clinic. Measurement of the rate of change of circulating tumour antigens was used for evaluating biological activity and defining optimum dosage in the early clinical trials of marimastat. Although tumour antigen levels have been used in the clinical management of cancer for many years, they have not been validated as markers of disease progression. In order to investigate the relationship between the effects of marimastat on tumour growth and circulating tumour antigen levels, mice bearing the human gastric tumour, MGLVA1, were treated with marimastat. The MMP inhibitor exerted a significant therapeutic effect, reducing tumour growth rate by 48% (P = 0.0005), and increasing median survival from 19 to 30 days (P = 0.0001). In addition, carcinoembryonic antigen (CEA) levels were measured in serum samples from animals sacrificed at regular intervals, and correlated with excised tumour weight. It was shown that the natural log of the CEA concentration was linearly related to the natural log of the tumour weight and that treatment was not a significant factor in this relationship (P = 0.7). In conclusion, circulating CEA levels were not directly affected by marimastat, but did reflect tumour size. These results support the use of cancer antigens as markers of biological activity in early phase trials of non-cytotoxic anticancer agents. © 1999 Cancer Research Campaign

Keywords: matrix metalloproteinases, marimastat, gastric carcinoma, tumour antigens

Full Text

The Full Text of this article is available as a PDF (97.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen-Mersh T. G., Kemeny N., Niedzwiecki D., Shurgot B., Daly J. M. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut. 1987 Dec;28(12):1625–1629. doi: 10.1136/gut.28.12.1625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson I. C., Shipp M. A., Docherty A. J., Teicher B. A. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 1996 Feb 15;56(4):715–718. [PubMed] [Google Scholar]
  3. Chirivi R. G., Garofalo A., Crimmin M. J., Bawden L. J., Stoppacciaro A., Brown P. D., Giavazzi R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994 Aug 1;58(3):460–464. doi: 10.1002/ijc.2910580326. [DOI] [PubMed] [Google Scholar]
  4. Davies B., Brown P. D., East N., Crimmin M. J., Balkwill F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993 May 1;53(9):2087–2091. [PubMed] [Google Scholar]
  5. Eccles S. A., Box G. M., Court W. J., Bone E. A., Thomas W., Brown P. D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 1996 Jun 15;56(12):2815–2822. [PubMed] [Google Scholar]
  6. Giavazzi R., Garofalo A., Ferri C., Lucchini V., Bone E. A., Chiari S., Brown P. D., Nicoletti M. I., Taraboletti G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998 Apr;4(4):985–992. [PubMed] [Google Scholar]
  7. Goldenberg D. M., Neville A. M., Carter A. C., Go V. L., Holyoke E. D., Isselbacher K. J., Schein P. S., Schwartz M. CEA (carcinoembryonic antigen): its role as a marker in the management of cancer. J Cancer Res Clin Oncol. 1981;101(3):239–242. doi: 10.1007/BF00410109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gore M., A'Hern R., Stankiewicz M., Slevin M. Tumour marker levels during marimastat therapy. Lancet. 1996 Jul 27;348(9022):263–264. doi: 10.1016/s0140-6736(96)24030-9. [DOI] [PubMed] [Google Scholar]
  9. Gore M., A'Hern R., Stankiewicz M., Slevin M. Tumour marker levels during marimastat therapy. Lancet. 1996 Jul 27;348(9022):263–264. doi: 10.1016/s0140-6736(96)24030-9. [DOI] [PubMed] [Google Scholar]
  10. Hine K. R., Dykes P. W. Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA. Gut. 1984 Jun;25(6):682–688. doi: 10.1136/gut.25.6.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Honda M., Mori M., Ueo H., Sugimachi K., Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut. 1996 Sep;39(3):444–448. doi: 10.1136/gut.39.3.444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Matrisian L. M. The matrix-degrading metalloproteinases. Bioessays. 1992 Jul;14(7):455–463. doi: 10.1002/bies.950140705. [DOI] [PubMed] [Google Scholar]
  13. McDonnell S., Navre M., Coffey R. J., Jr, Matrisian L. M. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4(6):527–533. doi: 10.1002/mc.2940040617. [DOI] [PubMed] [Google Scholar]
  14. Nemunaitis J., Poole C., Primrose J., Rosemurgy A., Malfetano J., Brown P., Berrington A., Cornish A., Lynch K., Rasmussen H. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998 May;4(5):1101–1109. [PubMed] [Google Scholar]
  15. Pimm M. V., Robins R. A., Baldwin R. W. Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice. J Cancer Res Clin Oncol. 1992;118(5):367–370. doi: 10.1007/BF01294441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Primrose J. N., Bleiberg H., Daniel F., Van Belle S., Mansi J. L., Seymour M., Johnson P. W., Neoptolemos J. P., Baillet M., Barker K. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer. 1999 Feb;79(3-4):509–514. doi: 10.1038/sj.bjc.6690079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sledge G. W., Jr, Qulali M., Goulet R., Bone E. A., Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst. 1995 Oct 18;87(20):1546–1550. doi: 10.1093/jnci/87.20.1546. [DOI] [PubMed] [Google Scholar]
  18. Stetler-Stevenson W. G., Hewitt R., Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996 Jun;7(3):147–154. doi: 10.1006/scbi.1996.0020. [DOI] [PubMed] [Google Scholar]
  19. Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., Brown P. D., Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst. 1995 Feb 15;87(4):293–298. doi: 10.1093/jnci/87.4.293. [DOI] [PubMed] [Google Scholar]
  20. Wang X., Fu X., Brown P. D., Crimmin M. J., Hoffman R. M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726–4728. [PubMed] [Google Scholar]
  21. Ward U., Primrose J. N., Finan P. J., Perren T. J., Selby P., Purves D. A., Cooper E. H. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer. 1993 May;67(5):1132–1135. doi: 10.1038/bjc.1993.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Watson S. A., Durrant L. G., Wencyk P. M., Watson A. L., Morris D. L. Intracellular gastrin in human gastrointestinal tumor cells. J Natl Cancer Inst. 1991 Jun 19;83(12):866–871. doi: 10.1093/jnci/83.12.866. [DOI] [PubMed] [Google Scholar]
  23. Watson S. A., Morris T. M., Robinson G., Crimmin M. J., Brown P. D., Hardcastle J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 1995 Aug 15;55(16):3629–3633. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES